社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Alvinbae
IP属地:海外
+关注
帖子 · 11
帖子 · 11
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
Alvinbae
Alvinbae
·
2021-03-15
真应该买跳楼险的
看
3,363
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Alvinbae
Alvinbae
·
2021-03-13
[流泪]
看
2,182
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Alvinbae
Alvinbae
·
2021-03-12
晚上又要大跌,提前出海散散心
看
2,519
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Alvinbae
Alvinbae
·
2021-03-09
累觉不爱
$朝云集团(06601)$
看
2,913
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Alvinbae
Alvinbae
·
2021-03-06
我有一个大胆的想法,求一女韭菜与我一起参与实验
看
2,026
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Alvinbae
Alvinbae
·
2021-03-04
子弹快用光了,行情见底还早[流泪]
看
2,797
回复
评论
点赞
1
编组 21备份 2
分享
举报
Alvinbae
Alvinbae
·
2021-02-28
15倍杠杆打一下朝云玩,期待20%收益。
看
6,471
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Alvinbae
Alvinbae
·
2021-02-27
今天被厂长骂了 说我拌的水泥太稀了 厂长把我的铁揪捶烂了 问我是不是水不要钱 我不敢反驳 他不知道的是 我没有多放水 只是拌水泥时看了眼大盘 眼泪掉进了水泥里
看
2,518
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Alvinbae
Alvinbae
·
2021-02-25
学会风险对冲,股市不亏钱
我买股是从不亏钱的,因为我有风险对冲。把8成仓位全买
$特斯拉(TSLA)$
,另外2成仓位买意外身亡险。特斯拉大涨我就赚,特斯拉大跌我就跳楼,赔率1:4,怎样都赚钱。所以买股要有一个好心态,学会风险对冲。
看
5,934
回复
7
点赞
5
编组 21备份 2
分享
举报
学会风险对冲,股市不亏钱
Alvinbae
Alvinbae
·
2021-02-25
诱导出货,韭菜们撑住啊
昭衍新药暗盘跌近8%,此前获310倍认购
2月25日消息,昭衍新药暗盘报139港元,较发行价跌7.95%。公司发行约4332.48万股股份,每股定价151港元,每手100股,将于2月26日(周五)港股上市。在此前的公开认购阶段,共有539,9
昭衍新药暗盘跌近8%,此前获310倍认购
看
2,457
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3575536960584993","uuid":"3575536960584993","gmtCreate":1612442937464,"gmtModify":1614222943663,"name":"Alvinbae","pinyin":"alvinbae","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/5c45c96cb311440e84799218b407918e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":29,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":3,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.25","exceedPercentage":"60.67%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"海外","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":322156072,"gmtCreate":1615786362896,"gmtModify":1703492931333,"author":{"id":"3575536960584993","authorId":"3575536960584993","name":"Alvinbae","avatar":"https://static.tigerbbs.com/5c45c96cb311440e84799218b407918e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575536960584993","authorIdStr":"3575536960584993"},"themes":[],"htmlText":"真应该买跳楼险的","listText":"真应该买跳楼险的","text":"真应该买跳楼险的","images":[{"img":"https://static.tigerbbs.com/8ee3601f66f7e1c3509a71fbc292d760","width":"1129","height":"1168"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/322156072","isVote":1,"tweetType":1,"viewCount":3363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":326891677,"gmtCreate":1615609149899,"gmtModify":1703491597599,"author":{"id":"3575536960584993","authorId":"3575536960584993","name":"Alvinbae","avatar":"https://static.tigerbbs.com/5c45c96cb311440e84799218b407918e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575536960584993","authorIdStr":"3575536960584993"},"themes":[],"htmlText":"[流泪] ","listText":"[流泪] ","text":"[流泪]","images":[{"img":"https://static.tigerbbs.com/c0e212aab747b353ac5651fd223d3df5","width":"600","height":"476"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/326891677","isVote":1,"tweetType":1,"viewCount":2182,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":328796131,"gmtCreate":1615558124923,"gmtModify":1703490891895,"author":{"id":"3575536960584993","authorId":"3575536960584993","name":"Alvinbae","avatar":"https://static.tigerbbs.com/5c45c96cb311440e84799218b407918e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575536960584993","authorIdStr":"3575536960584993"},"themes":[],"htmlText":"晚上又要大跌,提前出海散散心","listText":"晚上又要大跌,提前出海散散心","text":"晚上又要大跌,提前出海散散心","images":[{"img":"https://static.tigerbbs.com/e9447a0753991f505e59dc992a98a573","width":"3648","height":"2736"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/328796131","isVote":1,"tweetType":1,"viewCount":2519,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},{"id":329777336,"gmtCreate":1615284742825,"gmtModify":1703486749806,"author":{"id":"3575536960584993","authorId":"3575536960584993","name":"Alvinbae","avatar":"https://static.tigerbbs.com/5c45c96cb311440e84799218b407918e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575536960584993","authorIdStr":"3575536960584993"},"themes":[],"htmlText":"累觉不爱<a href=\"https://laohu8.com/S/06601\">$朝云集团(06601)$</a>","listText":"累觉不爱<a href=\"https://laohu8.com/S/06601\">$朝云集团(06601)$</a>","text":"累觉不爱$朝云集团(06601)$","images":[{"img":"https://static.tigerbbs.com/b7524c104bf6557d5fac9489cc744dd2","width":"413","height":"377"},{"img":"https://static.tigerbbs.com/6e13461f5b1107c7ffbe20712fdcf807","width":"300","height":"348"},{"img":"https://static.tigerbbs.com/98f38798ed407c9c150271501af3f5bb","width":"465","height":"463"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/329777336","isVote":1,"tweetType":1,"viewCount":2913,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},{"id":320396299,"gmtCreate":1615009978011,"gmtModify":1703484213791,"author":{"id":"3575536960584993","authorId":"3575536960584993","name":"Alvinbae","avatar":"https://static.tigerbbs.com/5c45c96cb311440e84799218b407918e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575536960584993","authorIdStr":"3575536960584993"},"themes":[],"htmlText":"我有一个大胆的想法,求一女韭菜与我一起参与实验","listText":"我有一个大胆的想法,求一女韭菜与我一起参与实验","text":"我有一个大胆的想法,求一女韭菜与我一起参与实验","images":[{"img":"https://static.tigerbbs.com/96ac927bcdba44ac203ccdc8ca83003b","width":"600","height":"928"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/320396299","isVote":1,"tweetType":1,"viewCount":2026,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":364931043,"gmtCreate":1614791133582,"gmtModify":1703481274450,"author":{"id":"3575536960584993","authorId":"3575536960584993","name":"Alvinbae","avatar":"https://static.tigerbbs.com/5c45c96cb311440e84799218b407918e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575536960584993","authorIdStr":"3575536960584993"},"themes":[],"htmlText":"子弹快用光了,行情见底还早[流泪] ","listText":"子弹快用光了,行情见底还早[流泪] ","text":"子弹快用光了,行情见底还早[流泪]","images":[{"img":"https://static.tigerbbs.com/80db086eac7944bd773c84e782cfb361","width":"300","height":"287"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/364931043","isVote":1,"tweetType":1,"viewCount":2797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":366234242,"gmtCreate":1614486062586,"gmtModify":1703477785658,"author":{"id":"3575536960584993","authorId":"3575536960584993","name":"Alvinbae","avatar":"https://static.tigerbbs.com/5c45c96cb311440e84799218b407918e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575536960584993","authorIdStr":"3575536960584993"},"themes":[],"htmlText":"15倍杠杆打一下朝云玩,期待20%收益。","listText":"15倍杠杆打一下朝云玩,期待20%收益。","text":"15倍杠杆打一下朝云玩,期待20%收益。","images":[{"img":"https://static.tigerbbs.com/1ec5a7f35e6ba36f3b9917f1d5c4db24","width":"750","height":"1334"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/366234242","isVote":1,"tweetType":1,"viewCount":6471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":366133874,"gmtCreate":1614406609298,"gmtModify":1703477365954,"author":{"id":"3575536960584993","authorId":"3575536960584993","name":"Alvinbae","avatar":"https://static.tigerbbs.com/5c45c96cb311440e84799218b407918e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575536960584993","authorIdStr":"3575536960584993"},"themes":[],"htmlText":"今天被厂长骂了 说我拌的水泥太稀了 厂长把我的铁揪捶烂了 问我是不是水不要钱 我不敢反驳 他不知道的是 我没有多放水 只是拌水泥时看了眼大盘 眼泪掉进了水泥里","listText":"今天被厂长骂了 说我拌的水泥太稀了 厂长把我的铁揪捶烂了 问我是不是水不要钱 我不敢反驳 他不知道的是 我没有多放水 只是拌水泥时看了眼大盘 眼泪掉进了水泥里","text":"今天被厂长骂了 说我拌的水泥太稀了 厂长把我的铁揪捶烂了 问我是不是水不要钱 我不敢反驳 他不知道的是 我没有多放水 只是拌水泥时看了眼大盘 眼泪掉进了水泥里","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/366133874","isVote":1,"tweetType":1,"viewCount":2518,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":361440140,"gmtCreate":1614257534680,"gmtModify":1614257672288,"author":{"id":"3575536960584993","authorId":"3575536960584993","name":"Alvinbae","avatar":"https://static.tigerbbs.com/5c45c96cb311440e84799218b407918e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575536960584993","authorIdStr":"3575536960584993"},"themes":[],"title":"学会风险对冲,股市不亏钱","htmlText":"我买股是从不亏钱的,因为我有风险对冲。把8成仓位全买<a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> ,另外2成仓位买意外身亡险。特斯拉大涨我就赚,特斯拉大跌我就跳楼,赔率1:4,怎样都赚钱。所以买股要有一个好心态,学会风险对冲。 ","listText":"我买股是从不亏钱的,因为我有风险对冲。把8成仓位全买<a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> ,另外2成仓位买意外身亡险。特斯拉大涨我就赚,特斯拉大跌我就跳楼,赔率1:4,怎样都赚钱。所以买股要有一个好心态,学会风险对冲。 ","text":"我买股是从不亏钱的,因为我有风险对冲。把8成仓位全买$特斯拉(TSLA)$ ,另外2成仓位买意外身亡险。特斯拉大涨我就赚,特斯拉大跌我就跳楼,赔率1:4,怎样都赚钱。所以买股要有一个好心态,学会风险对冲。","images":[{"img":"https://static.tigerbbs.com/9039ae86e99242d1a47d60c346b8ee6f","width":"0","height":"0"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":5,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/361440140","isVote":1,"tweetType":1,"viewCount":5934,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3546318738763437","authorId":"3546318738763437","name":"剥咯菠萝蜜","avatar":"https://static.tigerbbs.com/0ca3bbf80361d0e1c3935a20fc4f3176","crmLevel":2,"crmLevelSwitch":0,"idStr":"3546318738763437","authorIdStr":"3546318738763437"},"content":"跳楼身亡不属于意外保险公司不赔偿,保费不退","text":"跳楼身亡不属于意外保险公司不赔偿,保费不退","html":"跳楼身亡不属于意外保险公司不赔偿,保费不退"}],"imageCount":1,"langContent":"CN","totalScore":0},{"id":361224663,"gmtCreate":1614241215352,"gmtModify":1614241215352,"author":{"id":"3575536960584993","authorId":"3575536960584993","name":"Alvinbae","avatar":"https://static.tigerbbs.com/5c45c96cb311440e84799218b407918e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575536960584993","authorIdStr":"3575536960584993"},"themes":[],"htmlText":"诱导出货,韭菜们撑住啊","listText":"诱导出货,韭菜们撑住啊","text":"诱导出货,韭菜们撑住啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/361224663","repostId":"1141728873","repostType":4,"repost":{"id":"1141728873","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据,旨在帮助投资者理解世界,做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614240969,"share":"https://ttm.financial/m/news/1141728873?lang=&edition=full","pubTime":"2021-02-25 16:16","market":"hk","language":"zh","title":"昭衍新药暗盘跌近8%,此前获310倍认购","url":"https://stock-news.laohu8.com/highlight/detail?id=1141728873","media":"老虎资讯综合","summary":"2月25日消息,昭衍新药暗盘报139港元,较发行价跌7.95%。公司发行约4332.48万股股份,每股定价151港元,每手100股,将于2月26日(周五)港股上市。在此前的公开认购阶段,共有539,9","content":"<p><b>2月25日消息,<a href=\"https://laohu8.com/S/06127\">昭衍新药</a>暗盘报139港元,较发行价跌7.95%。公司发行约4332.48万股股份,每股定价151港元,每手100股,将于2月26日(周五)港股上市。</b><img src=\"https://static.tigerbbs.com/bae563a34cd6b757090979cb1eb78b96\" tg-width=\"741\" tg-height=\"1294\"></p><p>在此前的公开认购阶段,共有539,993人申购<b>昭衍新药</b>,中签人数80,829人,一手中签率5%,认购倍数达310倍。老虎资讯整理相关数据如下表:<img src=\"https://static.tigerbbs.com/2824aa41a845e6535a3e8aef655c3a70\" tg-width=\"1059\" tg-height=\"824\" referrerpolicy=\"no-referrer\"><b>分配结果:</b></p><p>甲组每手(100股)申购所需资金约15252.17港元,一手中签率5%,认购60手稳中一手。</p><p>乙组头为40000股,申购所需资金约6100865.08港元,获配500股(5手)。<img src=\"https://static.tigerbbs.com/a26817f20a5bc9611da25e5e6f53bd0a\" tg-width=\"603\" tg-height=\"709\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/7361e5faef06cbf3ba89b3c2a3b0ace1\" tg-width=\"609\" tg-height=\"539\" referrerpolicy=\"no-referrer\">据悉,公司是一家专注于药物非临床安全性评价的领先合同研究组织,正扩展以提供涵盖药物研发服务链上药物发现、临床前和临床试验阶段的综合服务。</p><p>根据弗若斯特沙利文的资料,现在公司已成为国内最大的药物非临床安全性评价合同研究组织,按2019年的收益计,市场份额为15.7%。公司A股自 2017年8月起已于上海证券交易所上市昭衍新药。</p><p>财务数据方面,公司2017财年至2019财年总收益分别为人民币3.01亿元、4.09亿元和6.39亿元,复合年增长率45.7%。同期录得净利润7991.7万元、1.05亿元和1.88亿元,复合年增长率53.2%。截至2020年9月30日止九个月,公司收入6.32亿港元,同比增长83.4%,净利润1.42亿元,同比增长65.1%。<img src=\"https://static.tigerbbs.com/ae3870625fddb6ee3a6dc1d723d1590a\" tg-width=\"781\" tg-height=\"498\" referrerpolicy=\"no-referrer\">行业方面,随着制药行业持续发展,合同研究组织在资金密集、复杂、具风险及耗时的药品研发流程中发挥着愈来愈重要的作用。合同研究组织提供涵盖(i)药物发现阶段、(ii)临床前阶段及(iii)临床阶段(包括I至IV期临床试验)的全面研发解决方案。<img src=\"https://static.tigerbbs.com/f85ad384c6259d4ac3c2ed7629340caf\" tg-width=\"1087\" tg-height=\"547\" referrerpolicy=\"no-referrer\">2019年中国及全球药物非临床安全性合同研究组织市场的市场规模分别为4.16亿美元及48亿美元,分别约占2019年中国及全球医药合同研究组织市场的市场规模68亿美元及626亿美元的6.1%及7.7%。</p><p>中国的非临床安全性评价(DSA)市场预计将在未来五年保持快速增长,于2024年达至19.67亿美元,复合年增长率为36.5%。</p><p>所得款项净额约62.86亿港元将用作以下用途:约16%将用于翻新现有设备及设施,建立新的实验模型繁殖及存货设施及雇佣经验丰富的专业人员;约10%增强公司的美国业务以迎合客户对Biomere所提供服务日益增长的需求;约39%将用于在广州及重庆建设新设施,雇佣经验丰富的专业人员,及发展尖端技术;约5%拓展及深化公司的综合合同研究组织服务;约20%为潜在收购提供资金;约10%将用于营运资金及一般企业用途。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>昭衍新药暗盘跌近8%,此前获310倍认购</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n昭衍新药暗盘跌近8%,此前获310倍认购\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-02-25 16:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>2月25日消息,<a href=\"https://laohu8.com/S/06127\">昭衍新药</a>暗盘报139港元,较发行价跌7.95%。公司发行约4332.48万股股份,每股定价151港元,每手100股,将于2月26日(周五)港股上市。</b><img src=\"https://static.tigerbbs.com/bae563a34cd6b757090979cb1eb78b96\" tg-width=\"741\" tg-height=\"1294\"></p><p>在此前的公开认购阶段,共有539,993人申购<b>昭衍新药</b>,中签人数80,829人,一手中签率5%,认购倍数达310倍。老虎资讯整理相关数据如下表:<img src=\"https://static.tigerbbs.com/2824aa41a845e6535a3e8aef655c3a70\" tg-width=\"1059\" tg-height=\"824\" referrerpolicy=\"no-referrer\"><b>分配结果:</b></p><p>甲组每手(100股)申购所需资金约15252.17港元,一手中签率5%,认购60手稳中一手。</p><p>乙组头为40000股,申购所需资金约6100865.08港元,获配500股(5手)。<img src=\"https://static.tigerbbs.com/a26817f20a5bc9611da25e5e6f53bd0a\" tg-width=\"603\" tg-height=\"709\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/7361e5faef06cbf3ba89b3c2a3b0ace1\" tg-width=\"609\" tg-height=\"539\" referrerpolicy=\"no-referrer\">据悉,公司是一家专注于药物非临床安全性评价的领先合同研究组织,正扩展以提供涵盖药物研发服务链上药物发现、临床前和临床试验阶段的综合服务。</p><p>根据弗若斯特沙利文的资料,现在公司已成为国内最大的药物非临床安全性评价合同研究组织,按2019年的收益计,市场份额为15.7%。公司A股自 2017年8月起已于上海证券交易所上市昭衍新药。</p><p>财务数据方面,公司2017财年至2019财年总收益分别为人民币3.01亿元、4.09亿元和6.39亿元,复合年增长率45.7%。同期录得净利润7991.7万元、1.05亿元和1.88亿元,复合年增长率53.2%。截至2020年9月30日止九个月,公司收入6.32亿港元,同比增长83.4%,净利润1.42亿元,同比增长65.1%。<img src=\"https://static.tigerbbs.com/ae3870625fddb6ee3a6dc1d723d1590a\" tg-width=\"781\" tg-height=\"498\" referrerpolicy=\"no-referrer\">行业方面,随着制药行业持续发展,合同研究组织在资金密集、复杂、具风险及耗时的药品研发流程中发挥着愈来愈重要的作用。合同研究组织提供涵盖(i)药物发现阶段、(ii)临床前阶段及(iii)临床阶段(包括I至IV期临床试验)的全面研发解决方案。<img src=\"https://static.tigerbbs.com/f85ad384c6259d4ac3c2ed7629340caf\" tg-width=\"1087\" tg-height=\"547\" referrerpolicy=\"no-referrer\">2019年中国及全球药物非临床安全性合同研究组织市场的市场规模分别为4.16亿美元及48亿美元,分别约占2019年中国及全球医药合同研究组织市场的市场规模68亿美元及626亿美元的6.1%及7.7%。</p><p>中国的非临床安全性评价(DSA)市场预计将在未来五年保持快速增长,于2024年达至19.67亿美元,复合年增长率为36.5%。</p><p>所得款项净额约62.86亿港元将用作以下用途:约16%将用于翻新现有设备及设施,建立新的实验模型繁殖及存货设施及雇佣经验丰富的专业人员;约10%增强公司的美国业务以迎合客户对Biomere所提供服务日益增长的需求;约39%将用于在广州及重庆建设新设施,雇佣经验丰富的专业人员,及发展尖端技术;约5%拓展及深化公司的综合合同研究组织服务;约20%为潜在收购提供资金;约10%将用于营运资金及一般企业用途。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/5b3b5e72649367d0aafd9bcbbca9bcd1","relate_stocks":{"06127":"昭衍新药"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141728873","content_text":"2月25日消息,昭衍新药暗盘报139港元,较发行价跌7.95%。公司发行约4332.48万股股份,每股定价151港元,每手100股,将于2月26日(周五)港股上市。在此前的公开认购阶段,共有539,993人申购昭衍新药,中签人数80,829人,一手中签率5%,认购倍数达310倍。老虎资讯整理相关数据如下表:分配结果:甲组每手(100股)申购所需资金约15252.17港元,一手中签率5%,认购60手稳中一手。乙组头为40000股,申购所需资金约6100865.08港元,获配500股(5手)。据悉,公司是一家专注于药物非临床安全性评价的领先合同研究组织,正扩展以提供涵盖药物研发服务链上药物发现、临床前和临床试验阶段的综合服务。根据弗若斯特沙利文的资料,现在公司已成为国内最大的药物非临床安全性评价合同研究组织,按2019年的收益计,市场份额为15.7%。公司A股自 2017年8月起已于上海证券交易所上市昭衍新药。财务数据方面,公司2017财年至2019财年总收益分别为人民币3.01亿元、4.09亿元和6.39亿元,复合年增长率45.7%。同期录得净利润7991.7万元、1.05亿元和1.88亿元,复合年增长率53.2%。截至2020年9月30日止九个月,公司收入6.32亿港元,同比增长83.4%,净利润1.42亿元,同比增长65.1%。行业方面,随着制药行业持续发展,合同研究组织在资金密集、复杂、具风险及耗时的药品研发流程中发挥着愈来愈重要的作用。合同研究组织提供涵盖(i)药物发现阶段、(ii)临床前阶段及(iii)临床阶段(包括I至IV期临床试验)的全面研发解决方案。2019年中国及全球药物非临床安全性合同研究组织市场的市场规模分别为4.16亿美元及48亿美元,分别约占2019年中国及全球医药合同研究组织市场的市场规模68亿美元及626亿美元的6.1%及7.7%。中国的非临床安全性评价(DSA)市场预计将在未来五年保持快速增长,于2024年达至19.67亿美元,复合年增长率为36.5%。所得款项净额约62.86亿港元将用作以下用途:约16%将用于翻新现有设备及设施,建立新的实验模型繁殖及存货设施及雇佣经验丰富的专业人员;约10%增强公司的美国业务以迎合客户对Biomere所提供服务日益增长的需求;约39%将用于在广州及重庆建设新设施,雇佣经验丰富的专业人员,及发展尖端技术;约5%拓展及深化公司的综合合同研究组织服务;约20%为潜在收购提供资金;约10%将用于营运资金及一般企业用途。","news_type":1,"symbols_score_info":{"06127":0.9}},"isVote":1,"tweetType":1,"viewCount":2457,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}